RainDance Technologies Announces Sale of RDT 1000, Sequence Enrichment Solution to Expression Analysis
Share:
LEXINGTON, MASSACHUSETTS, U.S.A., April 16, 2009 - RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the commercial sale of an RDT 1000 and Sequence Enrichment Solution to Expression Analysis, Inc., a leading provider of genomic services for clinical trials and research.
The RainDance solution will enable Expression Analysis to expand its service offerings to provide genomic researchers quality and efficient targeted sequencing on large sample numbers.
"As the market leader in genomic outsourcing for gene expression, genotyping, and resequencing analysis, we enable our service offerings using best-in-class systems. RainDance Technologies is clearly in this class, and we are proud to incorporate their technology to further expand our suite of services and look forward to offering expanded DNA sequencing applications," said Steve McPhail, President and Chief Executive Officer of Expression Analysis.
The announcement marks the first sale of the RainDance solution to a service provider. The solution consists of an RDT 1000, consumables kits, custom PCR primer libraries, and expert training.
"As a leading genomic service provider, Expression Analysis' decision to embrace our platform accelerates the ability of researchers to access our sequence enrichment technology," said Christopher McNary, President and Chief Executive Officer of RainDance Technologies.
The RDT 1000 and Sequence Enrichment Solution utilize RainDance's breakthrough RainStorm(TM) microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter-volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets, enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance's solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.
The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be available for shipment to Europe. For more information, contact info@raindancetech.com, call 781-861-6300, or visit the company's website at www.raindancetech.com.
About RainDance Technologies, Inc.
RainDance Technologies, Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company's RainStorm(TM) technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.
RainDance's initial application will focus on the targeted sequencing of the human genome - one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
For more information, please visit www.raindancetech.com.
RainStorm(TM) is a trademark of RainDance Technologies, Inc.
About Expression Analysis, Inc.
Expertise Beyond Expression - Providing whole genome to focused set gene expression and genotyping assays, along with sequencing services using RainDance Technologies, Illumina, Affymetrix, and Applied Biosystems. A leading provider of genomic services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissue specimens as well as nucleic acid isolation and bioinformatic services. The company's quality system follows CLSI guidelines and their CLIA-registered lab supports GLP compliance.
